ReviewPharmacoEconomics2026
What is the Value of Developing an HTA Process?
Review in PharmacoEconomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Health technology assessment (HTA) processes are becoming increasingly established and embedded in healthcare decision making around the world. Yet, there is limited evidence on whether HTA processes at the system level offer value for money to those presiding over their creation, such as governments and ministries of health. That is, whether the value of improvements in the health system exceed the costs. To address this issue, we outline the approaches adopted in a sample of recent evaluations of HTA systems and propose a set of considerations for measuring and valuing HTA processes. The scale and remit of the process can help identify the relevant system-level impacts of HTA such as those on productive efficiency and population health, health equity, guiding innovation and care pathways, and broader impacts. We further describe the methodological challenges and potential approaches to evaluating HTA including the appropriateness of approaches. The considerations discussed can reveal the potential for ill-designed HTA processes to generate less social value than intended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.